A detailed history of Royal Bank Of Canada transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 36,649 shares of DAWN stock, worth $468,740. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,649
Previous 7,115 415.09%
Holding current value
$468,740
Previous $98,000 420.41%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.72 - $16.03 $375,672 - $473,430
29,534 Added 415.09%
36,649 $510,000
Q2 2024

Aug 14, 2024

BUY
$12.03 - $17.69 $41,010 - $60,305
3,409 Added 91.99%
7,115 $98,000
Q1 2024

Nov 05, 2024

SELL
$13.56 - $17.46 $46,226 - $59,521
-3,409 Reduced 47.91%
3,706 $61,000
Q1 2024

May 15, 2024

SELL
$13.56 - $17.46 $237,489 - $305,794
-17,514 Reduced 82.54%
3,706 $61,000
Q4 2023

Feb 14, 2024

BUY
$9.68 - $15.37 $111,310 - $176,739
11,499 Added 118.29%
21,220 $309,000
Q3 2023

Nov 14, 2023

BUY
$11.22 - $14.86 $54,304 - $71,922
4,840 Added 99.16%
9,721 $119,000
Q2 2023

Aug 14, 2023

BUY
$11.74 - $14.47 $24,383 - $30,054
2,077 Added 74.07%
4,881 $58,000
Q1 2023

May 15, 2023

SELL
$12.75 - $23.41 $19,571 - $35,934
-1,535 Reduced 35.38%
2,804 $37,000
Q4 2022

Feb 14, 2023

BUY
$18.77 - $22.0 $53,156 - $62,304
2,832 Added 187.92%
4,339 $93,000
Q3 2022

Nov 14, 2022

BUY
$16.44 - $26.57 $3,797 - $6,137
231 Added 18.1%
1,507 $30,000
Q2 2022

Aug 15, 2022

SELL
$5.72 - $17.9 $7,241 - $22,661
-1,266 Reduced 49.8%
1,276 $22,000
Q1 2022

May 16, 2022

SELL
$9.12 - $17.47 $6,958 - $13,329
-763 Reduced 23.09%
2,542 $25,000
Q4 2021

Feb 14, 2022

BUY
$15.65 - $26.33 $30,188 - $50,790
1,929 Added 140.19%
3,305 $55,000
Q3 2021

Nov 15, 2021

BUY
$20.0 - $27.92 $27,520 - $38,417
1,376 New
1,376 $33,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $940M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.